Overview

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

Status:
Active, not recruiting

Trial end date:
2020-10-31

Target enrollment:

Participant gender:

Summary

Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.) to prevent device related thrombus.

Phase:

Phase 4

Details

Lead Sponsor:

Christopher Ellis
Vanderbilt University Medical Center

Collaborator:

Boehringer Ingelheim

Treatments:

Aspirin
Dabigatran